NCT01545375View on ClinicalTrials.gov

Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children

PHASE2CompletedINTERVENTIONAL
Enrollment

1,806

Participants

Timeline

Start Date

May 21, 2012

Primary Completion Date

July 26, 2016

Study Completion Date

July 26, 2016

Conditions
Infections, Streptococcal
Interventions
BIOLOGICAL

Pneumococcal vaccine GSK2189242A

4 doses administered intramuscularly

BIOLOGICAL

Placebo

4 doses administered intramuscularly

BIOLOGICAL

Prevnar 13®

4 doses administered intramuscularly

BIOLOGICAL

PedvaxHIB®

4 doses administered intramuscularly

Trial Locations (5)

85941

GSK Investigational Site, Whiteriver

86504

GSK Investigational Site, Fort Defiance

86505

GSK Investigational Site, Chinle

87301

GSK Investigational Site, Gallup

87420

GSK Investigational Site, Shiprock

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01545375 - Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children | Biotech Hunter | Biotech Hunter